Hsp90 molecular chaperone inhibitors Are we there yet.PDF

Hsp90 molecular chaperone inhibitors Are we there yet.PDF

ID:35522408

大小:570.47 KB

页数:22页

时间:2019-03-25

Hsp90 molecular chaperone inhibitors Are we there yet.PDF_第1页
Hsp90 molecular chaperone inhibitors Are we there yet.PDF_第2页
Hsp90 molecular chaperone inhibitors Are we there yet.PDF_第3页
Hsp90 molecular chaperone inhibitors Are we there yet.PDF_第4页
Hsp90 molecular chaperone inhibitors Are we there yet.PDF_第5页
资源描述:

《Hsp90 molecular chaperone inhibitors Are we there yet.PDF》由会员上传分享,免费在线阅读,更多相关内容在工程资料-天天文库

1、NeckersandWorkmanPage17Publishedinfinaleditedformas:ClinCancelRes.2012January1;18(1):64—76.doi:10.1158/1078-0432.CCR--1000.ClinCancerRes.Authormanuscript;availableinPMC2012July1•NeckersandWorkmanPage17NIH-PAAuthorManuscriptNIH-PAAuthorManuscriptNIH-bAAuthorManuscriptH

2、sp90molecularchaperoneinhibitors:Arewethereyet?LenNeckers1andPaulWorkman21UrologicOncologyBranch,CenterforCancerResearch,NationalCancerInstitute,9000RockvillePikeBldg.10/CRC,Room1-5940,Bethesda,MD20892-1107USA2SignalTransductionandMolecularPharmacologyTeam,CancerResea

3、rchUKCancerTherapeuticsUnit,DivisionofCancerTherapeutics,TheInstituteofCancerResearch,HaddowLaboratories,15CotswoldRoad,SuttonSM25NGUKAbstractHeatshockprotein(Hsp)90isanATP-dependentmolecularchaperoneexploitedbymalignantcellstosupportactivatedoncoproteins,includingman

4、ycancer-associatedkinasesandtranscriptionfactors,andisessentialforoncogenictransformation.Originallyviewedwithskepticism,Hsp90inhibitorsarenowactivelypursuedbythepharmaceuticalindustry,with17agentshavingenteredclinicaltrials.Hsp90’sdruggabilitywasestablishedusingthena

5、turalproductsgeldanamycinandradicicolwhichmimictheunusualATPstructureadoptedinthechaperone’sN-terminalnucleotide-bindingpocketandcausepotentandselectiveblockadeofATPbinding/hydrolysis,inhibitchaperonefunction,depleteoncogenicclients,anddemonstrateantitumoractivity.Pre

6、clinicaldatawiththesenaturalproductshaveheightenedinterestinHsp90asadrugtarget,and17-allylamino-17-demethoxygeldanamycin(17-AAG,tanespimycin)hasdemonstratedclinicalactivity(asdefinedbyRECISTcriteria)inHER2+breastcancer.ManyoptimizedsyntheticsmallmoleculeHsp90inhibitor

7、sfromdiversechemotypesarenowinclinicaltrials.WereviewthediscoveryanddevelopmentofHsp90inhibitorsandassesstheirfuturepotential.TherehasbeensignificantlearningfromexperienceinboththebasicbiologyandthetranslationaldrugdevelopmentaroundHsp90,enhancedbytheuseofHsp90inhibit

8、orsaschemicalprobes.Successwilllikelylieintreatingcancersaddictedtoparticulardriveroncogeneproducts,suchasHER2,ALK,EGFRandBR

当前文档最多预览五页,下载文档查看全文

此文档下载收益归作者所有

当前文档最多预览五页,下载文档查看全文
温馨提示:
1. 部分包含数学公式或PPT动画的文件,查看预览时可能会显示错乱或异常,文件下载后无此问题,请放心下载。
2. 本文档由用户上传,版权归属用户,天天文库负责整理代发布。如果您对本文档版权有争议请及时联系客服。
3. 下载前请仔细阅读文档内容,确认文档内容符合您的需求后进行下载,若出现内容与标题不符可向本站投诉处理。
4. 下载文档时可能由于网络波动等原因无法下载或下载错误,付费完成后未能成功下载的用户请联系客服处理。